# A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

> **NCT06337617** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- BRAF V600 Mutation Positive Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06337617
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-10
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337617, "A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06337617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*